AnaptysBio Target of Unusually Large Options Trading (NASDAQ:ANAB)

AnaptysBio Inc (NASDAQ:ANAB) was the target of some unusual options trading on Monday. Investors acquired 896 put options on the stock. This represents an increase of approximately 1,278% compared to the average daily volume of 65 put options.

AnaptysBio stock traded up $0.31 during mid-day trading on Tuesday, hitting $10.69. The company’s stock had a trading volume of 90,077 shares, compared to its average volume of 1,086,498. The firm’s 50 day moving average is $34.96 and its 200 day moving average is $52.67. The company has a market cap of $275.35 million, a PE ratio of -4.32 and a beta of 1.50. AnaptysBio has a 52-week low of $10.00 and a 52-week high of $83.10.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Friday, November 8th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.06). During the same period in the previous year, the firm earned ($0.66) earnings per share. As a group, equities analysts forecast that AnaptysBio will post -4.02 earnings per share for the current fiscal year.

Several analysts have recently weighed in on the company. Zacks Investment Research upgraded AnaptysBio from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a report on Wednesday, October 30th. JPMorgan Chase & Co. lowered AnaptysBio from an “overweight” rating to an “underweight” rating and cut their price objective for the company from $109.00 to $17.00 in a report on Friday. SunTrust Banks downgraded AnaptysBio from a “buy” rating to a “hold” rating in a report on Friday. Stifel Nicolaus reaffirmed a “hold” rating on shares of AnaptysBio in a report on Monday, September 30th. Finally, Wedbush downgraded AnaptysBio from an “outperform” rating to a “neutral” rating in a report on Friday. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company. AnaptysBio currently has an average rating of “Hold” and a consensus target price of $75.11.

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its stake in AnaptysBio by 13.4% in the 2nd quarter. BlackRock Inc. now owns 2,050,390 shares of the biotechnology company’s stock worth $115,681,000 after acquiring an additional 242,187 shares in the last quarter. Vanguard Group Inc. lifted its stake in AnaptysBio by 3.4% in the 2nd quarter. Vanguard Group Inc. now owns 1,985,144 shares of the biotechnology company’s stock worth $112,001,000 after acquiring an additional 65,527 shares in the last quarter. Invesco Ltd. lifted its stake in AnaptysBio by 25,030.8% in the 2nd quarter. Invesco Ltd. now owns 1,097,462 shares of the biotechnology company’s stock worth $61,919,000 after acquiring an additional 1,093,095 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in AnaptysBio by 18.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 937,273 shares of the biotechnology company’s stock worth $52,881,000 after acquiring an additional 147,292 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in AnaptysBio by 2.7% in the 2nd quarter. Northern Trust Corp now owns 265,554 shares of the biotechnology company’s stock worth $14,983,000 after acquiring an additional 7,062 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

Recommended Story: Resistance Level

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.